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Abstract 
Transcription factor MafA is a key molecule in insulin secretion and the development 
of pancreatic islets.  Previously, we demonstrated that some of the MafA-deficient 
mice develop overt diabetes mellitus, and the phenotype of these mice seems to be 
mild probably because of redundant functions of other Maf proteins.  In this study, 
we generated hybrid transgenic mice that were MafA-deficient and also 
overexpressed MafK specifically in beta cells (MafA-/-MafK+). MafA-/-MafK+ mice 
developed severe overt diabetes mellitus within 5 weeks old, and showed higher 
levels of proteinuria and serum creatinine.  Histological analysis revealed that 
embryonic development of beta cells in the MafA-/-MafK+ mice was significantly 
suppressed and the reduced number of beta cells was responsible for the early onset 
of diabetes.  Furthermore, after uninephrectomy, these mice demonstrated three 
characteristics of human diabetic nephropathy: diffuse, nodular, and exudative 
lesions.  MafA-/-MafK+ mice might be a useful model for the analysis of human 
diabetic nephropathy. 
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Introduction 
The transcription of genes that are involved in insulin production is regulated by 
a variety of transcription factors that are expressed specifically in pancreatic beta cells.  
It has been demonstrated that three conserved elements, A3, E1 and C1, which are 
found in the regulatory regions of the insulin genes, are indispensable for beta 
cell-specific insulin gene transcription [1-10].  Pancreatic duodenal homeobox factor-1 
(PDX-1) binds to the A3 element and is involved in both insulin gene expression and 
pancreatic development [4,7,9].  The transcription factor BETA2 binds to E1 elements 
and also plays an important role in insulin production and islet development [6].  The 
C1 element is a critical cis-acting sequence for insulin gene expression, and is bound 
by the RIPE3b1 transcriptional activator.  The gene that encodes the RIPE3b1 activator 
has been cloned and identified as MafA [8,10]. 
MafA is a member of Maf transcription factor family.  Maf family proteins 
contain a C-terminal basic leucine zipper domain that binds to specific DNA 
sequences that are named Maf recognition elements (MAREs), and mediates 
dimerization of the proteins.  Maf family proteins can be divided into two subgroups, 
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large and small Maf proteins, on the basis of presence or absence of an N-terminal 
activation domain.  The members of the small Maf protein family, which include 
MafK, MafF, and MafG [11,12], do not possess the transactivation domain.  These 
proteins can either act as transcriptional cofactors by forming heterodimers with 
members of the Cap ’n’ collar (CNC) transcription factor family or as transcriptional 
repressors by binding to target MARE sequences as homodimers.  The role that they 
play depends on the equilibrium concentrations of the CNC and small Maf proteins 
[13-16].  On the other hand, large Maf proteins contain an N-terminal activation 
domain and stimulate the transcription of target genes.  
MafA is important for insulin gene transcription. Therefore, we generated 
MafA-deficient (MafA-/-) mice and reported that these mice develop diabetes mellitus 
due to a decrease in insulin gene transcription, impaired glucose-stimulated insulin 
secretion and abnormalities of the pancreatic islets [17].  In spite of many previous 
reports that showed the importance of MafA for pancreatic beta cell function 
[2,8,18,19], the phenotype of MafA-/- mice seemed to be mild.  This mild phenotype 
might be explained by the presence of other large Maf proteins, MafB and/or c-Maf, 
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that can activate the expression of insulin genes and other MafA target genes 
[3,8,18,20].  In addition to the generation of MafA-/- mice, we also generated 
transgenic mice that overexpressed MafK specifically in beta cells (MafK+) mice [21].  
MafK, which is a small Maf protein, acts as a dominant negative protein to suppress 
the effect of large Maf proteins in pancreatic beta cells.  MafK+ mice demonstrated 
hyperglycemia at a young age, and then this phenotype disappeared.  Furthermore, 
MafK+ mice did not develop overt diabetes.  Detailed analysis of the mice revealed 
that up-regulation of endogenous MafA might compensate for the over-expression of 
MafK.  
In this study, we generated MafA-/- mice that over-expressed MafK in pancreatic 
beta cells (MafA-/-MafK+) mice in order to depress MafA protein and transcriptional 
activity of other large Maf proteins in the beta cells, and evaluated whether the 
MafA-/-MafK+ mice developed overt severe diabetes mellitus.  
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Materials and methods 
Animals. MafA-/- mice [17] and MafK+ mice [21] were generated as described 
previously.  All mice used were on an ICR genetic background.  MafA-/- female mice 
were interbred with MafK+ male mice.  The MafA-/-MafK+ mice were obtained from 
interbreeding of MafA+/-MafK+ and MafA-/- mice.  Male mice were used in this study.  
Mice were fed with normal diet and maintained in specific pathogen-free conditions 
in a Laboratory Animal Resource Center.  All experiments were performed according 
to the Guide for the Care and Use of Laboratory Animals at the University of Tsukuba, 
and the study was approved by the Institutional Review Board of the University.   
Measurements of serum glucose and insulin. The serum concentration of glucose in 
fed animals and in animals subjected to a 12 hours overnight fast was measured using 
a Dry-chem 3500 automated analyzer for routine laboratory tests (Fuji Film, Inc., 
Tokyo, Japan).  The serum insulin levels in fed animals were measured with a rat 
insulin ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan).   
Analysis of urinary protein excretion and renal serological assays. The urine of each 
mouse was collected in an individual metabolic cage over a 24 hours period.  The 
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amount of proteinuria was assessed by measuring the turbidity that was obtained 
with 3% sulphosalicylic acid.  The concentrations of serum albumin, creatinine, blood 
urea nitrogen, and total cholesterol were measured using the Dry-chem 3500 
analyzer.  
Histopathological analysis. The pancreas and one of the kidneys from each mouse 
were fixed with 10% formalin and embedded in paraffin.  Pancreatic sections were 
stained for histopathological examination with hematoxylin and eosin, and kidney 
sections were stained by the Periodic acid-Schiff (PAS).  For semiquantitative 
histological analysis, the area of 30 glomerular tufts in each kidney section was 
measured by the Image J image processing program (National Institutes of Health, 
Bethesda, MD).  The mean glomerular tuft was determined [22].  The other kidney 
from each mouse was snap-frozen and embedded in optimal cutting temperature 
compound for immunohistochemistry.  
Immunohistochemistry. Pancreatic sections were immunostained with both 
anti-insulin antibody (Linco Research, St. Louis, MO) and anti-glucagon antibody 
(DAKO, Glostrup, Denmark) to investigate the distribution of alpha and beta cells. 
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Detection was performed using fluorescein secondary antibodies (Cortex Biochem, 
San Leandro, CA and ZYMED, San Francisco, CA).  The frozen kidney sections were 
immunostained with anti-laminin antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) as the primary antibody and this was detected using the Histofine Kit 
(Nichirei, Tokyo, Japan).  
Uninephrectomy of mice. To perform uninephrectomy of the mice, the left renal 
artery and ureter were ablated in eight-week-old mice under anesthesia.  Twelve 
weeks after uninephrectomy, the mice were killed, the other kidney was removed and 
histological examination was carried out.  
Statistical analysis. All results were expressed as means ± SEM.  Multiple data 
comparisons were conducted using one-way analysis of variance (ANOVA) with the 
Bonferroni correction.  Differences were considered statistically significant at P values 
that were less than 0.05.  
 
11 
 
Results 
MafA-/-MafK+ mice developed overt diabetes mellitus at 5 weeks of age 
We first analyzed the blood glucose level of these mice.  MafA-/-MafK+ mice had 
already developed overt diabetes mellitus at 5 weeks of age (Table 1).  The blood 
glucose levels of MafA-/-MafK+ mice that had been fed were significantly higher than 
those of MafA-/- (P < 0.01), MafK+ (P < 0.01), or wild type (P < 0.01) mice at 5 weeks of 
age (Table 1).  Even after fasting, the blood glucose levels in the MafA-/-MafK+ mice 
were in excess of 500 mg/dl.  Female MafA-/-MafK+ mice displayed an almost 
identical phenotype to the male mice and hyperglycemia was detected during the 
observation period, which lasted for 30 weeks (data not shown).  Serum insulin levels 
in the MafA-/-MafK+ mice were lower than those in the wild type (P < 0.01), and 
MafK+ mice (P < 0.01).  In addition to hyperglycemia, the MafA-/-MafK+ mice showed 
growth retardation compared to wild type mice as their weight increased. We also 
evaluated the life span.  Survival rate of MafA-/-MafK+ mice (n=16) at 30 weeks was 
37.5%, but those of the other groups were all 100% (wild type (n=15), MafK+ (n=8), 
and MafA-/-mice (n=8)).  MafA-/-MafK+ mice had a short life span than the other 
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groups. 
 
Morphological analysis of pancreatic islets of MafA-/-MafK+ mice 
The size of the pancreatic islets in 20-week-old MafA-/-MafK+ mice was 
comparable with that of the wild type, MafK+, and MafA-/-mice (Fig. 1G, A, C and E).  
However, immunohistochemical analysis revealed that, although the mean total cell 
number for each islet was not significantly different between the wild type and 
MafA-/-MafK+ mice, the islets in the MafA-/-MafK+ mice were occupied by 
glucagon-positive cells (Fig. 1H).  As we demonstrated previously, this pancreatic 
islet abnormality is one of the main phenotype of MafA-/- mice.  In MafA-/-MafK+ 
mice, the abnormal architecture of the islets, in particular the decrease in the number 
of beta cells and increase in the number of alpha cells, was more severe than in 
MafA-/- mice (Fig. 1H and F).  This abnormal distribution of alpha and beta cells was 
observed from birth (Fig. 1J).   
 
MafA-/-MafK+ mice exhibit diabetic nephropathy-like phenotype upon biochemical examination 
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Due to the fact that MafA-/-MafK+ mice developed severe diabetes mellitus at an 
early age and survived without insulin treatment, we thought that it might be 
possible to use these mice as a model for diabetic nephropathy.  Predictably, these 
mice demonstrated polyuria, and displayed increased proteinuria, serum total 
cholesterol and blood urea nitrogen as compared with wild type mice (Table 2).  This 
phenotype is similar to the nephrotic syndrome observed in human diabetic 
nephropathy.  Moreover, there was a significant elevation of the serum creatinine 
level in MafA-/-MafK+ mice.   
 
Histological analysis of the kidneys of MafA-/-MafK+ mice 
Next, we performed histological analysis of kidneys from 20-week-old 
MafA-/-MafK+ mice. Glomerular hypertrophy and mesangial matrix expansion, 
which are the most characteristic lesions of diabetic nephropathy [22] were observed 
in PAS-stained kidney sections from MafA-/-MafK+ mice (Fig. 2G).  In fact, the 
glomerular surface area in the sections from MafA-/-MafK+ mice was significantly 
larger than in the sections from wild type mice as determined by quantitative analysis 
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(Fig. 3).  The ratio of the mean glomerular surface area of MafA-/-MafK+ mice to that 
of wild mice was 1.79 ± 0.09.  Furthermore, the kidney weight to body weight ratio of 
the MafA-/-MafK+ mice was also significantly heavier than those of the wild type mice 
(Table 2).  To analyze mesangial matrix expansion, we performed 
immunohistochemical staining of laminin, since laminin is a component of the 
mesangial matrix [22]. We detected strong anti-laminin staining and confirmed that 
glomerular matrix expansion had occurred in the MafA-/-MafK+ mice (Fig. 2H).   
 
Uninephrectomy of MafA-/-MafK+ mice caused the nodular-like lesions that are observed in 
human diabetic nephropathy 
To increase the load on a single glomerulus, we performed uninephrectomy in 
8-week-old wild type, MafK+, MafA-/- and MafA-/-MafK+ mice.  Twelve weeks after 
uninephrectomy, only MafA-/-MafK+ mice showed impairment of renal function 
upon serological testing (Table 3), and histological examination.   MafA-/-MafK+ mice 
after uninephrectomy demonstrated a more severe mesangial matrix expansion than 
that of MafA-/-MafK+ mice (Fig. 4D).  On the other hand, MafA-/-, MafK+, and wild 
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type mice showed no change after uninephrectomy (Fig. 4 A,B,C).  Moreover, the 
kidneys of the MafA-/-MafK+ mice contained diffuse lesions characterized by a 
widespread increase in periodic acid-Schiff-positive material within the mesangium 
in textbook [23], nodular lesions, and exudative lesions, all of which are observed in 
severe human diabetic nephropathy (Fig. 4 E,F,G).   
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Discussion 
MafA-/-MafK+ mice displayed a more severe phenotype than the MafA-/- mice, 
and developed diabetes mellitus at a younger age.  Histological analysis 
demonstrated that the pancreatic islets of MafA-/-MafK+ mice were almost completely 
occupied by glucagon-producing alpha cells.  This phenotype could be explained by 
the results of recent reports and our own preliminary observations.  Nishimura et al. 
and Artner et al. have demonstrated that MafB is expressed in both alpha and beta 
cells during embryonic development and that MafB deficiency induces a reduction in 
the mass of both alpha and beta cells [24,25].  Due to the fact that we demonstrated 
previously that the number of alpha and beta cells in new born MafA-/- mice is not 
abnormal [17], this suggested that MafB is a key large Maf factor in the development 
of alpha and beta cells during embryogenesis.  This idea is also supported by our 
preliminary observation that MafA-/-MafB-/- embryos display an almost same 
reduction in both alpha and beta cells as that seen in MafB-/- embryos at 18.5 days 
(data not shown).  MafK, which acts as dominant negative protein to inhibit the 
activity of large Maf proteins, may suppress MafB function specifically in beta cells, 
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thus inducing a phenotype that resembles that of the MafB-deficient embryos.  
However, MafK is not expressed in the alpha cells and would not interfere with MafB 
function in these cells.  Therefore, alpha cell expansion would be induced in the 
embryos.   
As we have demonstrated in this paper, MafA-/-MafK+ mice have the potential to 
become a new model for diabetic nephropathy.  These mice developed diabetes 
mellitus before 5 weeks of age and began to demonstrate polyuria at this time.  In the 
biochemical analysis, increased creatinine, blood urea nitrogen, total cholesterol and 
proteinuria excretion were observed in the MafA-/-MafK+ mice.  The histological 
appearance of kidney sections from the MafA-/-MafK+ mice showed more severe 
glomerular hypertrophy and mesangial matrix expansion than in those from wild 
type, MafK+ and MafA-/- mice.  These data suggested that the renal phenotype of our 
hybrid transgenic mice is similar to human diabetic nephropathy.   
Human diabetes mellitus is classified into four types: type 1, type 2, other specific 
types and gestational diabetes [26].  Type 1 diabetes mellitus is characterized by the 
destruction of beta cell due to an autoimmune process, and this usually leads to 
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insulin deficiency.  Type 2 diabetes mellitus is characterized by insulin resistance in 
peripheral tissues and insufficient insulin secretion by the beta cells.  This is highly 
associated with a family history of diabetes, older age, obesity and lack of exercise.  
The mouse models of diabetes are also classified as type 1 or type 2 diabetes mellitus 
[27].  MafA-/-MafK+ mice developed diabetes at an early age because of inadequate 
embryonic development of beta cells, but did not show autoimmune pancreatitis or 
obesity after birth.  In this sense, it is difficult to classify MafA-/-MafK+ mice simply as 
a model of type 1, or 2, diabetes, although the MafA-/-MafK+ mouse is a good animal 
model for hyperglycemia.  
The major deficiency in animal models of diabetic nephropathy is the absence of 
severe human-like diabetic histopathological findings [27].  The db/db mouse is one 
of the most well known models of diabetic nephropathy [28].  This mouse shows 
hyperglycemia at 8 weeks of age and after 4-6 weeks of hyperglycemia, mesangial 
matrix expansion is observed.  The level of mesangial matrix expansion and 
glomerular hypertrophy in the db/db mice is mild compared to that in the 
MafA-/-MafK+ mouse.  In addition, most mouse models of diabetes show 
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gender-specific differences in their phenotype and the appearance of nodular lesions 
in these mice is rare [22].  However, in the MafA-/-MafK+ mouse, both male and 
female mice developed diabetes mellitus at 5 weeks of age, and hyperglycemia 
persisted throughout the observation period.  Furthermore, after uninephrectomy, 
nodular lesions, which are the representative histological feature of human diabetic 
nephropathy, were found in our mice.  In the mouse models, diffuse lesions, nodular 
lesions and exudative lesions are generally absent and we could not detect nodular 
lesions in 20-week-old MafA-/-MafK+ mice [27].  Uninephrectomy has been used 
experimentally to enhance the development of diabetic nephropathy [29,30].  
MafA-/-MafK+ mice demonstrated three characteristics of human diabetic 
nephropathy after uninephrectomy: diffuse lesions, nodular lesions, and exudative 
lesions.  From these results, we conclude that MafA-/-MafK+ mice might provide a 
new mouse model for diabetes and useful tool for analyzing the pathogenesis of 
human diabetic nephropathy.  
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Figures legends 
Fig. 1. Histopathological examination of pancreatic islets.  Hematoxylin and eosin 
staining of pancreatic islets in 20-week-old wild type (A), MafK+ (C), MafA-/- (E) and 
MafA-/-MafK+ mice (G).  Magnification is x 50 and each bar represents 100 μm.  
Immunohistochemistry of pancreatic islets.  Immunofluorescence staining of insulin 
(red) and glucagon (green) in 20-week-old wild type (B), MafK+ (D), MafA-/- (F) and 
MafA-/-MafK+ mice (H).  Magnification is x 100 and each bar represents 100 μm.  
Immunofluorescence staining of insulin (red) and glucagon (green) in wild type (I), 
and MafA-/-MafK+ mice (J) on postnatal day 1.  Magnification is x 200 and each bar 
represents 20 μm.  
 
Fig. 2. Histological examination of the kidney.  Periodic acid-Schiff staining in 
20-week-old wild type (A), MafK+ (C), MafA-/- (E) and MafA-/-MafK+ mice (G).  
Magnification is x 200 and each bar represents 100 μm.  Immunohistochemical 
staining of laminin in 20-week-old wild type (B), MafK+ (D), MafA-/- (F) and 
MafA-/-MafK+ mice (H).  Magnification is x 350 and each bar represents 100 μm.   
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Fig. 3. Semiquantitative histological analysis of glomerular surface area in 
20-week-old wild type (n = 5), MafK+ (n = 5), MafA-/- (n = 5) and MafA-/-MafK+ (n = 5) 
mice.  The ratios of the mean glomerular tufts of MafA-/-MafK+ mice were 
significantly larger than that of MafK+, MafA-/- and wild type mice.  *P < 0.01.   
 
Fig. 4. Histological examination of wild type (A), MafK+ (B), MafA-/- (C) and 
MafA-/-MafK+ (D) mice at 12 weeks after uninephrectomy.  Magnification is x 200. 
Diffuse lesions are observed at a magnification of x 600 (E), exudative lesions at a 
magnification of x 600 (F), and nodular lesions at a magnification of x 600 (G).  The 
arrowhead shows an exudative lesion, and the arrows show nodular lesions.  Periodic 
acid-Schiff staining.  Each bar represents 100 μm.   
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Table 1  Biochemical data of the experimental mice. 
 Wild MafK+ MafA-/- MafA-/-MafK+ 
n  8   7   7   6  
Serum             
 Glucose (5W) (mg/dl) 175.7 ± 8.1 226.7 ± 5.3 217.6 ± 10.5 900.8 ± 84.6* 
 Glucose (10W) (mg/dl) 173.0 ± 8.2 193.6 ± 11.1 167.6 ± 8.8 999.4 ± 104.2* 
 Glucose (20W) (mg/dl) 159.8 ± 38.3 158.0 ± 21.6 252.3 ± 35.2 853.3 ± 64.1* 
 Insulin (10W) (ng/ml) 0.93 ± 0.09 1.49 ± 0.20* 0.66 ± 0.2 0.28 ± 0.10* 
Body weight (5W) (g) 25.2 ± 1.0 24.9 ± 0.5 26.4 ± 0.4 23.0 ± 0.6 
Body weight (10W) (g) 35.1 ± 0.5 32.2 ± 0.8* 30.8 ± 1.1* 25.8 ± 1.5* 
Body weight (20W) (g) 40.8 ± 0.8 34.3 ± 0.8* 38.7 ± 0.7 27.9 ± 1.0* 
Values are expressed as means ± SEM.  Wild, wild type.  
*P< 0.01 compared with Wild mice.  
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Table 2  Biochemical data of the experimental mice 
 Wild MafK+ MafA-/- MafA-/-MafK+ 
n  7   6   5   5  
Serum             
 ALB (10W) (g/dl) 2.2 ± 0.0 2.2 ± 0.0 2.4 ± 0.1 1.9 ± 0.1**
 ALB (20W) (g/dl) 2.6 ± 0.1 2.1 ± 0.1* 2.2 ± 0.1** 1.8 ± 0.1* 
 CRE (10W) (mg/dl) 0.35 ± 0.01 0.34 ± 0.02 0.38 ± 0.02 0.42 ± 0.02* 
 CRE (20W) (mg/dl) 0.34 ± 0.04 0.37 ± 0.06 0.41 ± 0.03 0.48 ± 0.04** 
 BUN (10W) (mg/dl) 20.6 ± 1.1 23.4 ± 0.9 24.3 ± 3.1 39.6 ± 3.5* 
 BUN (20W) (mg/dl) 26.3 ± 3.5 30.9 ± 6.7 27.0 ± 3.0 45.0 ± 7.8** 
 T-CHO (10W) (mg/dl) 155.2 ± 4.5 104.0 ± 7.7** 143.0 ± 30.3 207.8 ± 23.8** 
 T-CHO (20W) (mg/dl) 124.0 ± 6.1 98.3 ± 19.3 142.5 ± 10.6 260.0 ± 30.5* 
Urinary             
 Protein (10W) (mg/day) 3.5 ± 0.6 3.7 ± 1.0 4.4 ± 1.7 10.8 ± 2.4* 
 Protein (20W) (mg/day) 4.9 ± 1.6 5.7 ± 0.8 3.9 ± 1.8 8.8 ± 2.3 
Kidney/BW (20W) (%) 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 1.9 ± 0.3* 
Values are expressed as means ± SEM.  Wild, wild type. ALB, albumin; CRE, creatinine; BUN, blood 
urea nitrogen; T-CHO, total cholesterol; BW, body weight.  Kidney, the mean weight of kidneys.  
*P < 0.01 compared with Wild mice.   
**P < 0.05 compared with Wild mice.   
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Table 3  Biochemical data after uninephrectomy 
 Wild MafK+ MafA-/- MafA-/-MafK+ 
n  3   5   3   3  
Serum             
 Glucose (20W) (mg/dl) 164.0 ± 14.4 210.6 ± 13.4 173.0 ± 19.7 1033.0 ± 55.9* 
 CRE (20W) (mg/dl) 0.37 ± 0.03 0.37  ± 0.02 0.35 ± 0.06 0.52 ± 0.04** 
 BUN (20W) (mg/dl) 32.0 ± 1.5 35.8 ± 2.7 33.3 ± 2.2 53.4 ± 7.0* 
Urinary             
 Protein (20W) (mg/day) 1.9 ± 0.5 2.7 ± 0.6 1.7 ± 0.3 4.2 ± 0.3* 
Kidney/BW (20W) (%) 1.1 ± 0.0 0.9 ± 0.1 1.1 ± 0.1 2.4 ± 0.3* 
Values are expressed as means±SEM.  Wild, wild type.  CRE, creatinine; BUN, blood urea nitrogen; 
BW, body weight.  Kidney, a single kidney weight.  
*P < 0.01 compared with Wild mice.   
**P < 0.05 compared with Wild mice.   
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